SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kayla N. Ellefsen, Ariane Wohlfarth, Madeleine J. Swortwood, Xingxing Diao, Marta Concheiro, Marilyn A. Huestis, 4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry, Forensic Toxicology, 2016, 34, 1, 61

    CrossRef

  2. 2
    Sinead E. Shortall, Clare H. Spicer, Francis J. P. Ebling, A. Richard Green, Kevin C. F. Fone, Madeleine V. King, Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone, Addiction Biology, 2016, 21, 2
  3. 3
    Igor Linhart, Michal Himl, Monika Židková, Marie Balíková, Eva Lhotková, Tomáš Páleníček, Metabolic profile of mephedrone: Identification of nor-mephedrone conjugates with dicarboxylic acids as a new type of xenobiotic phase II metabolites, Toxicology Letters, 2016, 240, 1, 114

    CrossRef

  4. You have free access to this content4
    Adam R. Winstock, Will Lawn, Paolo Deluca, Rohan Borschmann, Methoxetamine: An early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample, Drug and Alcohol Review, 2016, 35, 2
  5. 5
    Rachel Sutherland, Amy Peacock, Elizabeth Whittaker, Amanda Roxburgh, Simon Lenton, Allison Matthews, Kerryn Butler, Marina Nelson, Lucinda Burns, Raimondo Bruno, New psychoactive substance use among regular psychostimulant users in Australia, 2010–2015, Drug and Alcohol Dependence, 2016, 161, 110

    CrossRef

  6. 6
    Andrés Ciudad-Roberts, Leticia Duart-Castells, Jorge Camarasa, David Pubill, Elena Escubedo, The combination of ethanol with mephedrone increases the signs of neurotoxicity and impairs neurogenesis and learning in adolescent CD-1 mice, Toxicology and Applied Pharmacology, 2016, 293, 10

    CrossRef

  7. 7
    Elli Tyrkkö, Mikael Andersson, Robert Kronstrand, The Toxicology of New Psychoactive Substances, Therapeutic Drug Monitoring, 2016, 38, 2, 190

    CrossRef

  8. 8
    Mariana Angoa-Pérez, Donald M. Kuhn, Neuropathology of Drug Addictions and Substance Misuse, 2016,

    CrossRef

  9. 9
    Francesco S. Romolo, Paola A. Fiore, Edoardo Bottoni, Simone Cappelletti, Mariarosaria Aromatario, Costantino Ciallella, Neuropathology of Drug Addictions and Substance Misuse, 2016,

    CrossRef

  10. 10
    John H. Anneken, Mariana Angoa-Pérez, Donald M. Kuhn, 3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter, Journal of Neurochemistry, 2015, 133, 2
  11. 11
    Andrés Ciudad-Roberts, Jorge Camarasa, Carlos J. Ciudad, David Pubill, Elena Escubedo, Alcohol enhances the psychostimulant and conditioning effects of mephedrone in adolescent mice; postulation of unique roles of D3 receptors and BDNF in place preference acquisition, British Journal of Pharmacology, 2015, 172, 20
  12. 12
    Yasuko Fuse-Nagase, Fukumi Saito, Toshie Hirohara, Happei Miyakawa, Awareness survey of so-called Dappou drugs or Kiken drugs (New Psychoactive Substances) among University Students in Japan, Substance Abuse Treatment, Prevention, and Policy, 2015, 10, 1

    CrossRef

  13. 13
    Michael D. Berquist, M. Melissa Peet, Lisa E. Baker, Behavioral sensitization following concurrent exposure to mephedrone and D-amphetamine in female mice, Behavioural Pharmacology, 2015, 26, 180

    CrossRef

  14. 14
    Michael F Weaver, John A Hopper, Erik W Gunderson, Designer drugs 2015: assessment and management, Addiction Science & Clinical Practice, 2015, 10, 1, 8

    CrossRef

  15. 15
    Michael Shiner, Adam Winstock, Drug use and social control: The negotiation of moral ambivalence, Social Science & Medicine, 2015, 138, 248

    CrossRef

  16. 16
    Máté Kapitány-Fövény, Barbara Mervó, Máté Kertész, Ornella Corazza, Judit Farkas, Gyöngyi Kökönyei, Róbert Urbán, Zsolt Demetrovics, Is there any difference in patterns of use and psychiatric symptom status between injectors and non-injectors of mephedrone?, Human Psychopharmacology: Clinical and Experimental, 2015, 30, 4
  17. 17
    Raúl López-Arnau, José Martínez-Clemente, Teresa Rodrigo, David Pubill, Jorge Camarasa, Elena Escubedo, Neuronal changes and oxidative stress in adolescent rats after repeated exposure to mephedrone, Toxicology and Applied Pharmacology, 2015, 286, 1, 27

    CrossRef

  18. 18
    Claire Garnett, David Crane, Robert West, Susan Michie, Jamie Brown, Adam Winstock, Normative misperceptions about alcohol use in the general population of drinkers: A cross-sectional survey, Addictive Behaviors, 2015, 42, 203

    CrossRef

  19. 19
    Novel psychoactive substances: second and third international conferences, Human Psychopharmacology: Clinical and Experimental, 2015, 30, 4
  20. 20
    Hanna Uosukainen, Ulrich Tacke, Adam R. Winstock, Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users, International Journal of Drug Policy, 2015, 26, 1, 78

    CrossRef

  21. 21
    Ryan A Gregg, Michael H Baumann, John S Partilla, Julie S Bonano, Alexandre Vouga, Christopher S Tallarida, Venkata Velvadapu, Garry R Smith, M Melissa Peet, Allen B Reitz, S Stevens Negus, Scott M Rawls, Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats, British Journal of Pharmacology, 2015, 172, 3
  22. 22
    Jonathan Taylor, The Stimulants of Prohibition: Illegality and New Synthetic Drugs, Territory, Politics, Governance, 2015, 3, 4, 407

    CrossRef

  23. 23
    József Rácz, Róbert Csák, Sándor Lisznyai, Transition from “old” injected drugs to mephedrone in an urban micro segregate in Budapest, Hungary: a qualitative analysis, Journal of Substance Use, 2015, 20, 3, 178

    CrossRef

  24. 24
    Elisabetta Bertol, Francesco Mari, Rafael Boscolo Berto, Guido Mannaioni, Fabio Vaiano, Donata Favretto, A mixed MDPV and benzodiazepine intoxication in a chronic drug abuser: Determination of MDPV metabolites by LC–HRMS and discussion of the case, Forensic Science International, 2014, 243, 149

    CrossRef

  25. 25
    Marie Claire Van Hout, An Internet Study of User’s Experiences of the Synthetic Cathinone 4-Methylethcathinone (4-MEC), Journal of Psychoactive Drugs, 2014, 46, 4, 273

    CrossRef

  26. 26
    Christopher L. German, Annette E. Fleckenstein, Glen R. Hanson, Bath salts and synthetic cathinones: An emerging designer drug phenomenon, Life Sciences, 2014, 97, 1, 2

    CrossRef

  27. 27
    Ryan A. Gregg, Scott M. Rawls, Behavioral pharmacology of designer cathinones: A review of the preclinical literature, Life Sciences, 2014, 97, 1, 27

    CrossRef

  28. 28
    Mariana Angoa-Pérez, Michael J. Kane, Nieves Herrera-Mundo, Dina M. Francescutti, Donald M. Kuhn, Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus, Life Sciences, 2014, 97, 1, 31

    CrossRef

  29. 29
    Michael E. Nelson, Sean M. Bryant, Steven E. Aks, Emerging drugs of abuse, Disease-a-Month, 2014, 60, 3, 110

    CrossRef

  30. 30
    Michael E. Nelson, Sean M. Bryant, Steven E. Aks, Emerging Drugs of Abuse, Emergency Medicine Clinics of North America, 2014, 32, 1, 1

    CrossRef

  31. 31
    Peter F. Weed, Stuart T. Leonard, Ananthakrishnan Sankaranarayanan, Peter J. Winsauer, Estradiol administration to ovariectomized rats potentiates mephedrone-induced disruptions of nonspatial learning, Journal of the Experimental Analysis of Behavior, 2014, 101, 2
  32. 32
    Patrick S. Johnson, Matthew W. Johnson, Investigation of “Bath Salts” Use Patterns Within an Online Sample of Users in the United States, Journal of Psychoactive Drugs, 2014, 46, 5, 369

    CrossRef

  33. 33
    Caroline Sastre, Cédric Mazoyer, Charlotte Mayer, Jérôme Grosjean, Vincent Di Fazio, Élodie Saussereau, Les cathinones : qu’en sait-on aujourd’hui ?, Toxicologie Analytique et Clinique, 2014, 26, 3, 148

    CrossRef

  34. 34
    Christopher L. German, Mario E. Alburges, Amanda J. Hoonakker, Annette E. Fleckenstein, Glen R. Hanson, Mephedrone alters basal ganglia and limbic dynorphin systems, Synapse, 2014, 68, 12
  35. 35
    Jolanta B. Zawilska, Mephedrone and other cathinones, Current Opinion in Psychiatry, 2014, 27, 4, 256

    CrossRef

  36. 36
    Louise Karlsson, Mikael Andersson, Robert Kronstrand, Fredrik C. Kugelberg, Mephedrone, Methylone and 3,4-Methylenedioxypyrovalerone (MDPV) Induce Conditioned Place Preference in Mice, Basic & Clinical Pharmacology & Toxicology, 2014, 115, 5
  37. 37
    Jane Carlisle Maxwell, Psychoactive substances—Some new, some old: A scan of the situation in the U.S., Drug and Alcohol Dependence, 2014, 134, 71

    CrossRef

  38. 38
    Kristyn Tekulve, Andreia Alexander, Laura Tormoehlen, Seizures Associated With Synthetic Cathinone Exposures in the Pediatric Population, Pediatric Neurology, 2014, 51, 1, 67

    CrossRef

  39. You have free access to this content39
    A R Green, M V King, S E Shortall, K C F Fone, The preclinical pharmacology of mephedrone; not just MDMA by another name, British Journal of Pharmacology, 2014, 171, 9
  40. 40
    Suzanne Franki, Sarah B. Johnson, Trends and Treatment of Adolescent Street Drug Use, Child and Adolescent Psychopharmacology News, 2014, 19, 3, 5

    CrossRef

  41. 41
    Karla D. Wagner, Richard F. Armenta, Alexis M. Roth, Jane C. Maxwell, Jazmine Cuevas-Mota, Richard S. Garfein, Use of synthetic cathinones and cannabimimetics among injection drug users in San Diego, California, Drug and Alcohol Dependence, 2014, 141, 99

    CrossRef

  42. 42
    Andreas Büttner, The Effects of Drug Abuse on the Human Nervous System, 2014,

    CrossRef

  43. 43
    Gerald Scott Winder, Nathan Stern, Avinash Hosanagar, Are “Bath Salts” the next generation of stimulant abuse?, Journal of Substance Abuse Treatment, 2013, 44, 1, 42

    CrossRef

  44. 44
    Sinead E. Shortall, Alice E. Macerola, Rabbi T.R. Swaby, Rebecca Jayson, Chantal Korsah, Katharine E. Pillidge, Peter M. Wigmore, Francis J.P. Ebling, A. Richard Green, Kevin C.F. Fone, Madeleine V. King, Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat, European Neuropsychopharmacology, 2013, 23, 9, 1085

    CrossRef

  45. 45
    Karen Miotto, Joan Striebel, Arthur K. Cho, Christine Wang, Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports, Drug and Alcohol Dependence, 2013, 132, 1-2, 1

    CrossRef

  46. 46
    Kurt J. Varner, Kyle Daigle, Peter F. Weed, Peter B. Lewis, Sarah E. Mahne, Ananthakrishnan Sankaranarayanan, Peter J. Winsauer, Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats, Psychopharmacology, 2013, 225, 3, 675

    CrossRef

  47. 47
    Jolanta B. Zawilska, Jakub Wojcieszak, Designer cathinones—An emerging class of novel recreational drugs, Forensic Science International, 2013, 231, 1-3, 42

    CrossRef

  48. 48
    SE Shortall, AR Green, KM Swift, KCF Fone, MV King, Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia, British Journal of Pharmacology, 2013, 168, 4
  49. 49
    Paul Griffiths, Michael Evans-Brown, Roumen Sedefov, Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age, Addiction, 2013, 108, 10
  50. 50
    Erik W. Gunderson, Matthew G. Kirkpatrick, Laura M. Willing, Christopher P. Holstege, Intranasal Substituted Cathinone “Bath Salts” Psychosis Potentially Exacerbated by Diphenhydramine, Journal of Addiction Medicine, 2013, 7, 3, 163

    CrossRef

  51. 51
    Aymeric Petit, Laurent Karila, Michel Sananes, Michel Lejoyeux, La méphédrone : une nouvelle drogue de synthèse, La Presse Médicale, 2013, 42, 10, 1310

    CrossRef

  52. 52
    Bjørnar den Hollander, Stanislav Rozov, Anni-Maija Linden, Mikko Uusi-Oukari, Ilkka Ojanperä, Esa R. Korpi, Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone, Pharmacology Biochemistry and Behavior, 2013, 103, 3, 501

    CrossRef

  53. 53
    Ryan A. Gregg, Christopher S. Tallarida, Allen Reitz, Christopher McCurdy, Scott M. Rawls, Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats, Drug and Alcohol Dependence, 2013, 133, 2, 746

    CrossRef

  54. 54
    Mariana Angoa-Pérez, Michael J. Kane, Denise I. Briggs, Dina M. Francescutti, Catherine E. Sykes, Mrudang M. Shah, David M. Thomas, Donald M. Kuhn, Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA, Journal of Neurochemistry, 2013, 125, 1
  55. 55
    Ryan A. Gregg, Christopher S. Tallarida, Allen B. Reitz, Scott M. Rawls, Mephedrone interactions with cocaine, Behavioural Pharmacology, 2013, 24, 8, 684

    CrossRef

  56. 56
    J. Martínez-Clemente, R. López-Arnau, M. Carbó, D. Pubill, J. Camarasa, E. Escubedo, Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics, Psychopharmacology, 2013, 229, 2, 295

    CrossRef

  57. 57
    Nicholas F. Dybdal-Hargreaves, Nicholas D. Holder, Paige E. Ottoson, Melanie D. Sweeney, Tyisha Williams, Mephedrone: Public health risk, mechanisms of action, and behavioral effects, European Journal of Pharmacology, 2013, 714, 1-3, 32

    CrossRef

  58. 58
    Les Iversen, Simon Gibbons, Ric Treble, Vincent Setola, Xi-Ping Huang, Bryan L. Roth, Neurochemical profiles of some novel psychoactive substances, European Journal of Pharmacology, 2013, 700, 1-3, 147

    CrossRef

  59. 59
    Raoul Koning, Raymond Niesink, Nieuwe Psychoactieve Stoffen (NPS): niets nieuws onder de zon, Verslaving, 2013, 9, 1, 47

    CrossRef

  60. 60
    Erik W. Gunderson, Matthew G. Kirkpatrick, Laura M. Willing, Christopher P. Holstege, Substituted Cathinone Products, Journal of Addiction Medicine, 2013, 7, 3, 153

    CrossRef

  61. 61
    Máté Kapitány-Fövény, Máté Kertész, Adam Winstock, Paolo Deluca, Ornella Corazza, Judit Farkas, Gábor Zacher, Róbert Urbán, Zsolt Demetrovics, Substitutional potential of mephedrone: an analysis of the subjective effects, Human Psychopharmacology: Clinical and Experimental, 2013, 28, 4
  62. 62
    Bryan Wilson, Hamid Tavakoli, Daniel DeCecchis, Vimukta Mahadev, Synthetic Cannabinoids, Synthetic Cathinones, and Other Emerging Drugs of Abuse, Psychiatric Annals, 2013, 43, 12, 558

    CrossRef

  63. 63
    Adam R. Winstock, Monica J. Barratt, Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample, Drug and Alcohol Dependence, 2013, 131, 1-2, 106

    CrossRef

  64. 64
    Adam R. Winstock, Monica J. Barratt, The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products, Human Psychopharmacology: Clinical and Experimental, 2013, 28, 4
  65. 65
    Janie Sheridan, Christine Yang Dong, Rachael Butler, Joanne Barnes, The impact of New Zealand's 2008 prohibition of piperazine-based party pills on young people's substance use: Results of a longitudinal, web-based study, International Journal of Drug Policy, 2013, 24, 5, 412

    CrossRef

  66. 66
    Fermin Barrueto, Rajender Gattu, Maryann Mazer-Amirshahi, Updates in the General Approach to the Pediatric Poisoned Patient, Pediatric Clinics of North America, 2013, 60, 5, 1203

    CrossRef

  67. 67
    David M. Wood, Paul I. Dargan, Novel Psychoactive Substances, 2013,

    CrossRef

  68. 68
    Mark M. McGraw, ¿Consume su paciente “sales de baño”?, Nursing (Ed. española), 2012, 30, 4, 20

    CrossRef

  69. 69
    Marie Claire Van Hout, Tim Bingham, “A Costly Turn On”: Patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors, International Journal of Drug Policy, 2012, 23, 3, 188

    CrossRef

  70. 70
    Tom P. Freeman, Celia J. A. Morgan, James Vaughn-Jones, Nahida Hussain, Kash Karimi, H. Valerie Curran, Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’, Addiction, 2012, 107, 4
  71. 71
    Raul López-Arnau, Jose Martínez-Clemente, David Pubill, Elena Escubedo, Jorge Camarasa, Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone, British Journal of Pharmacology, 2012, 167, 2
  72. 72
    Pai-Kai Huang, Shawn M. Aarde, Deepshikha Angrish, Karen L. Houseknecht, Tobin J. Dickerson, Michael A. Taffe, Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats, Drug and Alcohol Dependence, 2012, 126, 1-2, 168

    CrossRef

  73. 73
    Laura Lindsay, Marjorie Lee White, Herbal Marijuana Alternatives and Bath Salts—“Barely Legal” Toxic Highs, Clinical Pediatric Emergency Medicine, 2012, 13, 4, 283

    CrossRef

  74. 74
    Christopher D. Rosenbaum, Stephanie P. Carreiro, Kavita M. Babu, Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines, Journal of Medical Toxicology, 2012, 8, 1, 15

    CrossRef

  75. 75
    Paolo Deluca, Zoe Davey, Ornella Corazza, Lucia Di Furia, Magi Farre, Liv Holmefjord Flesland, Miia Mannonen, Aino Majava, Teuvo Peltoniemi, Manuela Pasinetti, Cinzia Pezzolesi, Norbert Scherbaum, Holger Siemann, Arvid Skutle, Marta Torrens, Peer van der Kreeft, Erik Iversen, Fabrizio Schifano, Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 2, 221

    CrossRef

  76. 76
    Mark M. McGraw, Is your patient high on “bath salts”?, Nursing, 2012, 42, 1, 26

    CrossRef

  77. 77
    Mark M. McGraw, Is your patient high on “bath salts”?, Nursing Critical Care, 2012, 7, 6, 31

    CrossRef

  78. 78
    J. Elliott Robinson, Abigail E. Agoglia, Eric W. Fish, Michael C. Krouse, C.J. Malanga, Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: Comparison to cocaine, Behavioural Brain Research, 2012, 234, 1, 76

    CrossRef

  79. 79
    David M. Wood, Paul I. Dargan, Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 2, 227

    CrossRef

  80. 80
    Craig P. Motbey, Glenn E. Hunt, Michael T. Bowen, Suzanne Artiss, Iain S. McGregor, Mephedrone (4-methylmethcathinone, ‘meow’): acute behavioural effects and distribution of Fos expression in adolescent rats, Addiction Biology, 2012, 17, 2
  81. 81
    MJ Wright, Jr, SA Vandewater, D Angrish, TJ Dickerson, MA Taffe, Mephedrone (4-methylmethcathinone) and d-methamphetamine improve visuospatial associative memory, but not spatial working memory, in rhesus macaques, British Journal of Pharmacology, 2012, 167, 6
  82. 82
    Rebekah Brennan, Marie Claire Van Hout, Miaow miaow: a review of the new psychoactive drug mephedrone, Drugs and Alcohol Today, 2012, 12, 4, 241

    CrossRef

  83. 83
    Markus R. Meyer, Christian Vollmar, Andrea E. Schwaninger, Ehud (Udi) Wolf, Hans H. Maurer, New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC–MS and LC–high-resolution MS and their detectability in urine, Journal of Mass Spectrometry, 2012, 47, 2
  84. 84
    M. Perrin, Y. Lecompte, O. Roussel, R. Le Boisselier, J. Bourgine, A. Coquerel, Traité De Toxicologie Médico-judiciaire, 2012,

    CrossRef